Literature DB >> 7555104

Chronic idiopathic urticaria associated with panic disorder: a syndrome responsive to selective serotonin reuptake inhibitor antidepressants?

M A Gupta1, A K Gupta.   

Abstract

We present two patients with a history of chronic idiopathic urticaria occurring in conjunction with a panic disorder (DSM-IIIR), in whom both the urticaria and panic disorder responded favorably to a course of the selective serotonin reuptake inhibitor antidepressants fluoxetine and sertraline, respectively. Both patients had previously required systemic corticosteroids to manage their urticaria. Panic disorder is an anxiety disorder characterized by the presence of recurrent unexpected panic attacks. Serotoninergic mechanisms play an important role in panic disorder. In contrast to antidepressants such as doxepin, which have previously been found to be effective in the treatment of chronic urticaria, the newer selective serotonin reuptake inhibitor antidepressants are only weakly antihistaminic and anticholinergic. The response of both the urticaria and panic disorder to selective serotonin reuptake inhibitor antidepressants may suggest a common pathogenic factor involving serotoninergic mechanisms.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7555104

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  4 in total

Review 1.  Psychocutaneous disorders.

Authors:  D G Folks; J K Warnock
Journal:  Curr Psychiatry Rep       Date:  2001-06       Impact factor: 5.285

2.  Rash Associated With Panic Attacks.

Authors:  Shady S Shebak; James Pinkston; Rizwan Ali
Journal:  Prim Care Companion CNS Disord       Date:  2016-02-11

3.  Psychodermatology: a guide to understanding common psychocutaneous disorders.

Authors:  Mohammad Jafferany
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 4.  Psychiatric comorbidity in chronic urticaria patients: a systematic review and meta-analysis.

Authors:  Gerasimos N Konstantinou; George N Konstantinou
Journal:  Clin Transl Allergy       Date:  2019-08-23       Impact factor: 5.871

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.